Cefadroxil (BL-S 578)
(Synonyms: 头孢羟氨苄; BL-S 578) 目录号 : GC32099
Cefadroxil (BL-S 578) 是一种头孢菌素类广谱抗生素，对革兰氏阳性和革兰氏阴性细菌感染有效。
Cas No.:50370-12-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefadroxil is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections.
| Cas No. | 50370-12-2 | SDF | |
| 别名 | 头孢羟氨苄; BL-S 578 | ||
| Canonical SMILES | O=C(C(N12)=C(C)CS[C@]2([H])[C@H](NC([C@H](N)C3=CC=C(O)C=C3)=O)C1=O)O | ||
| 分子式 | C16H17N3O5S | 分子量 | 363.39 |
| 溶解度 | Water : 9.17 mg/mL (25.23 mM; ultrasonic and adjust pH to 3 with HCl) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7519 mL | 13.7593 mL | 27.5186 mL |
| 5 mM | 0.5504 mL | 2.7519 mL | 5.5037 mL |
| 10 mM | 0.2752 mL | 1.3759 mL | 2.7519 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs"
Int J Antimicrob Agents 2020 Oct;56(4):106085.PMID:32659466DOI:10.1016/j.ijantimicag.2020.106085.
First-generation oral cephalosporins (cephalexin and Cefadroxil) have traditionally been considered second-line treatment options for uncomplicated lower urinary tract infections (uLUTIs). However, in the current age of "bad bugs, few drugs", where there are increasingly limited oral options against resistant Enterobacteriaceae, there is an urgent need to rethink how best to utilize the available antibiotic armamentarium. This review examines the historical clinical trials and experimental studies of cephalexin and Cefadroxil, particularly through the modern lens of pharmacokinetics/pharmacodynamics (PK/PD), to better appreciate the efficacy of these drugs in uLUTIs. Furthermore, newer cefazolin-cephalexin surrogate testing, as recommended by the Clinical and Laboratory Standards Institute (CLSI) and the United States Committee on Antimicrobial Susceptibility Testing (USCAST), has recategorized cephalexin in many instances from resistant to susceptible. We conclude that cephalexin and Cefadroxil have very good early bacteriological and clinical cures in uLUTIs due to non-extended-spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae comparable to many traditionally first-line agents. Cephalexin can be conveniently administered as 500 mg twice or thrice daily, similar to Cefadroxil (500 mg twice daily); therefore, either agent may be used as a fluoroquinolone-sparing alternative. Cephalexin may be the more practical choice for many clinicians because reliable antimicrobial susceptibility test interpretative criteria (STIC) are provided by CLSI, USCAST, and the European Committee on Antimicrobial Susceptibility Testing (EUCAST), whereas direct Cefadroxil STIC is offered only by EUCAST.
Laboratory studies with BL-S 578 (Cefadroxil) a new broad-spectrum orally active cephalosporin
Chemotherapy 1979;25(1):9-13.PMID:33784DOI:10.1159/000237816.
BL-S 578 (Cefadroxil) is a new orally active semisynthetic cephalosporin antibiotic with broad-spectrum antibacterial activity. The new compound was evaluated in vitro in comparison with cephalexin. Some properties studies such as, antibacterial activity, binding with serum proteins and stability in acid and neutral solution at 37 degrees C for both cephalosporins were similar. In experimental infections of mice, the protective action of BL-S 578 was more effective than cephalexin against Staphylococcus aureus and Streptococcus pneumoniae. BL-S 578 was more resistant than cephalexin to the beta-lactamases produced by Klebsiella pneumoniae and Escherichia coli.
Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections
Microbiol Spectr 2022 Aug 31;10(4):e0103922.PMID:35730963DOI:10.1128/spectrum.01039-22.
Cephalexin and Cefadroxil are oral first-generation cephalosporins used to treat methicillin-susceptible Staphylococcus aureus (MSSA) infections. Despite its shorter half-life, cephalexin is more frequently prescribed, although Cefadroxil is an appealing alternative, given its slower clearance and possibility for less frequent dosing. We report comparative MIC distributions for Cefadroxil and cephalexin, as well as for oxacillin, cephalothin, ceftaroline, and cefazolin, for 48 unique clinical MSSA isolates from pediatric patients with musculoskeletal infections. Both Cefadroxil and cephalexin had MIC50 values of 2 μg/mL and MIC90 values of 4 μg/mL. MIC50s for oxacillin, cephalothin, and ceftaroline were ≿.25 μg/mL, and cefazolin's MIC50 was 0.5 μg/mL. While Cefadroxil and cephalexin MICs are higher than those for other active agents, the distributions of MICs for Cefadroxil and cephalexin are statistically equivalent, suggesting similar in vitro MSSA activities. Cefadroxil should be further considered an alternative agent to cephalexin, although additional work is needed to identify the optimal dose and frequency of these antibiotics for the treatment of serious MSSA infections. IMPORTANCE Cephalexin and Cefadroxil are oral antibiotics that are used to treat serious infections due to the bacteria MSSA. While cephalexin is used more commonly, Cefadroxil is excreted from the body more slowly; this generally allows patients to take Cefadroxil less frequently than cephalexin. In this study, we compared the abilities of Cefadroxil, cephalexin, and several other representative intravenous antibiotics to inhibit the growth of MSSA in the laboratory. Bacterial samples were obtained from children with bone, joint, and/or muscle infections caused by MSSA. We found that Cefadroxil and cephalexin inhibited the growth of MSSA at similar concentrations, suggesting similar antibacterial potencies. The selected intravenous antistaphylococcal antibiotics generally inhibited bacterial growth with lower antibiotic concentrations. Based on these results, Cefadroxil should be further considered an alternative oral antibiotic to cephalexin, although future research is needed to identify the optimal dose and frequency of these antibiotics for serious infections.
Serum levels and urinary excretion in humans of BL-S 578 (Cefadroxil), a new semisynthetic cephalosporin
Chemotherapy 1980;26(2):98-102.PMID:7363712DOI:10.1159/000237889.
Single doses of 250 and 500 mg of BL-S 578 (Cefadroxil), a new semisynthetic cephalosporin, were orally administered to 13 normal, healthy volunteers and serum levels determined at timed intervals for 7 h. Peak concentration was obtained at 1 1/2 h after administration of 250 mg (8.981 micrograms/ml) or 500 mg (17.861 micrograms/ml). Urniary excretion levels within 24 h after ingestion of single doses of 250 and 500 mg of Cefadroxil were 89.92 and 86.34%, respectively.
Cefadroxil Use for Musculoskeletal Infections in an Academic Pediatric Hospital
J Pediatric Infect Dis Soc 2022 Dec 28;11(12):590-593.PMID:36112393DOI:10.1093/jpids/piac104.
Forty-nine of 52 (94.2%) children with musculoskeletal infection (MSKI) were successfully treated with Cefadroxil dosed at 30 mg/kg/day over a 10-year time period. Two failures were associated with poor medication adherence. Our study suggests that treatment of MSKI with Cefadroxil offers acceptable outcomes. Confirmation through clinical trials is appropriate.